Back to News
Market Impact: 0.15
Spinogenix Announces Phase 2b Trial for Autism Using Novel Brain-Wave Screening to Target Treatment
Source: PR Newswire
Healthcare & Biotech
A first-of-its-kind prospective trial in neurodevelopmental drug development will enroll patients with elevated gamma-band EEG power. The accompanying research suggests this EEG characteristic is present in roughly 1 in 5 people with autism and nearly 1 in 3 adults; the excerpt provides no trial results or further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
More News
- Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
- Supernus Pharmaceuticals stock hits 52-week low at 40.5 USD
- Top biotechnology stock pick from Guggenheim
- Liquidia shares surge 25% as settlement ends United Therapeutics litigation
- Needham raises Starling Oncology stock price target on growth outlook
- Why is Olympus stock plunging today?
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Evaluate Consensus Estimates Platforms With AI
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More